Prognose
Analytikernes gennemsnitlige kursmål er 62,55 € (+85,06 %). Medianen er 61,06 € (+80,65 %).
| Køb |
21 |
| Behold |
1 |
| Sælg |
0 |
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
Xenon prepares NDA submission for Azetukalner, plans specialized sales team
Xenon said at the Wells Fargo Healthcare Conference that it plans to file the New Drug Application (NDA) for Azetukalner later this month and expects all four doses (10, 15, 20, 25 mg) to be included in the prescribing information. The company intends a premium pricing strategy with a single price across all strengths and is building a commercial team of about 150 employees, including a field force of roughly 75, to reduce market access barriers. Xenon emphasized the novel Kv7 mechanism of action but anticipates a slow, stepwise launch pattern for epilepsy products; global approval plans will be supported by the ongoing Phase III X‑TOLE3 study. In parallel, Xenon is advancing programs in depression (X‑NOVA) and NaV1.7 pain, and aims to have a fully integrated commercial biopharma structure by the end of 2027. » Mere på de.investing.com
Xenon Pharmaceuticals presents phase‑3 and long‑term data on epilepsy drug Azetukalner at epilepsy congress
Xenon Pharmaceuticals will present six Azetukalner presentations at the 16th European Epilepsy Congress (5–9 September 2026, Athens), including an oral presentation of the phase‑3 X-TOLE2 study in focal onset seizures. The data include results from the randomized, double‑blind, placebo‑controlled X-TOLE2 (380 participants; Azetukalner 25 mg or 15 mg vs. placebo) and findings from patients with at least 48 months of participation in the open‑label extension. In addition, mechanistic posters will show data on possible additive effects in combination with common antiseizure medications and in‑vivo evidence; Azetukalner is a potassium channel opener in development for epilepsy, major depressive disorder and bipolar depression. » Mere på de.investing.com
Xenon Pharmaceuticals stock hits all-time high of $63.96
Xenon Pharmaceuticals’ share rose to a record high of $63.96, marking a yearly increase of 102.36% and a YTD gain of 35%, with market capitalization around $6.2 billion. Analysts still see strong buy consensus and maintain a high price target of $100; the stock trades near its fair value. Q1 2026 results painted a mixed picture: EPS of -$1.17 slightly beat estimates, while no revenue was reported, missing expectations. » Mere på de.investing.com
Xenon Pharmaceuticals presents phase‑3 and long‑term data on azetukalner at AAN congress
Xenon Pharmaceuticals will present five abstracts at the American Academy of Neurology annual meeting, including results from the phase‑3 X‑TOLE2 study of azetukalner in focal seizures in a late‑breaking oral session and a poster session. The company will also present 48‑month interim analyses from the open‑label extension study X‑TOLE and real‑world data on titration burden and quality of life. In addition, Xenon will show preclinical data on its NaV1.1 program; azetukalner is described as a potassium channel opener being evaluated in phase‑3 studies for epilepsy and depressive disorders. » Mere på de.investing.com
Driehaus boosts stake in Xenon Pharmaceuticals after Phase 3 breakthrough
Driehaus Capital Management bought 369,577 shares of Xenon Pharmaceuticals in Q4, a $15.5 million trade that raised its position to about $203.4 million (1.4% of AUM). Xenon reported strong Phase 3 results for azetukalner in focal onset seizures and plans a U.S. regulatory filing later this year. The company also completed a $747.5 million public offering, shares jumped over 30% in days and are up about 66% over the past year. » Mere på finance.yahoo.com
Virksomhedstal
I det seneste kvartal havde Xenon Pharmaceuticals en omsætning på 0 € og et nettoresultat på -97,5 mio. €
| (EUR) | september 2026 | YoY |
|---|---|---|
| Omsætning | 0 | - |
| Bruttofortjeneste | 0 | 100,00 % |
| Nettoresultat | -97,5 mio. | 25,88 % |
| EBITDA | -95,37 mio. | 24,95 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 3,32 mia. € |
Antal aktier | 98,28 mio. |
Højeste/laveste i 52 uger | 66,22 € - 30,42 € |
| Udbytte | Nej |
Beta | 0,60 |
P/E (PE Ratio) | -7,88 |
PEG (PEG Ratio) | 0,42 |
K/I (PB Ratio) | 3,22 |
P/S (PS Ratio) | 0,00 |
Virksomhedsprofil
Xenon Pharmaceuticals Inc., et klinisk fase biofarmaceutisk selskab, udvikler terapier til behandling af patienter med neurologiske lidelser i Canada. Selskabets kliniske udviklingspipeline omfatter XEN496, en Kv7-kaliumkanalåbner, der er i fase III kliniske forsøg til behandling af KCNQ2 udviklingsmæssig og epileptisk encefalopati; og XEN1101, en Kv7-kaliumkanalåbner, som er i fase II klinisk forsøg til behandling af epilepsi og andre neurologiske lidelser. Selskabets produktkandidater omfatter også NBI-921352, en selektiv Nav1.6-natriumkanalhæmmer, der er i fase II kliniske forsøg til behandling af SCN8A udviklingsmæssig og epileptisk encefalopati samt andre potentielle indikationer, herunder voksen fokal epilepsi; og XEN007, en calciumkanalmodulator, der virker i centralnervesystemet, og som er i fase II kliniske forsøg. Selskabet har en licens- og samarbejdsaftale med Neurocrine Biosciences, Inc. om udvikling af behandlinger for epilepsi; og med Flexion Therapeutics, Inc. om udvikling af PCRX301 (XEN402, en Nav1.7-hæmmer) til behandling af postoperativ smerte. Xenon Pharmaceuticals Inc. blev stiftet i 1996 og har hovedkontor i Burnaby, Canada.
| Navn | Xenon Pharmaceuticals |
| CEO | Ian C. Mortimer |
| Hjemsted | Burnaby,
bc Canada |
| Websted | |
| Sektor | Materialer |
| Branche | Kemikalier |
| Børsnotering | 05.11.2014 |
| Medarbejdere | 364 |
Tickersymboler
| Børs | Symbol |
|---|---|
NASDAQ | XENE |
Frankfurt | XP0.F |
Düsseldorf | XP0.DU |
München | XP0.MU |